These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 20402598)

  • 1. An overview of investigational antiapoptotic drugs with potential application for the treatment of neurodegenerative disorders.
    Camins A; Sureda FX; Junyent F; Verdaguer E; Folch J; Beas-Zarate C; Pallas M
    Expert Opin Investig Drugs; 2010 May; 19(5):587-604. PubMed ID: 20402598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiapoptotic drugs: a therapautic strategy for the prevention of neurodegenerative diseases.
    Sureda FX; Junyent F; Verdaguer E; Auladell C; Pelegri C; Vilaplana J; Folch J; Canudas AM; Zarate CB; Pallès M; Camins A
    Curr Pharm Des; 2011; 17(3):230-45. PubMed ID: 21348832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Flavopiridol: an antitumor drug with potential application in the treatment of neurodegenerative diseases.
    Pallàs M; Verdaguer E; Jordà EG; Jiménez A; Canudas AM; Camins A
    Med Hypotheses; 2005; 64(1):120-3. PubMed ID: 15533627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospects for antiapoptotic drug therapy of neurodegenerative diseases.
    Waldmeier PC
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Apr; 27(2):303-21. PubMed ID: 12657369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Melatonin prevents glutamate-induced oxytosis in the HT22 mouse hippocampal cell line through an antioxidant effect specifically targeting mitochondria.
    Herrera F; Martin V; García-Santos G; Rodriguez-Blanco J; Antolín I; Rodriguez C
    J Neurochem; 2007 Feb; 100(3):736-46. PubMed ID: 17263795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent clinical failures in Parkinson's disease with apoptosis inhibitors underline the need for a paradigm shift in drug discovery for neurodegenerative diseases.
    Waldmeier P; Bozyczko-Coyne D; Williams M; Vaught JL
    Biochem Pharmacol; 2006 Nov; 72(10):1197-206. PubMed ID: 16901468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroprotective properties of resveratrol in different neurodegenerative disorders.
    Albani D; Polito L; Signorini A; Forloni G
    Biofactors; 2010; 36(5):370-6. PubMed ID: 20848560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interrupting apoptosis in neurodegenerative disease: potential for effective therapy?
    Waldmeier PC; Tatton WG
    Drug Discov Today; 2004 Mar; 9(5):210-8. PubMed ID: 14980539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The antiapoptotic activity of melatonin in neurodegenerative diseases.
    Wang X
    CNS Neurosci Ther; 2009; 15(4):345-57. PubMed ID: 19818070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Is good old minocycline a new neuroprotective drug?].
    Melero-Fernández de Mera RM; García-Martínez E; Fernández-Gómez FJ; Hernández-Guijo JM; Aguirre N; Galindo MF; Jordán J
    Rev Neurol; 2008 Jul 1-15; 47(1):31-8. PubMed ID: 18592478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Society for Neuroscience - 39th Annual Meeting. Part 2 - Novel therapies for neurodegenerative disorders and other CNS diseases.
    Al-Shamahi A; Kirkham K; Hookes L
    IDrugs; 2009 Dec; 12(12):734-7. PubMed ID: 19943211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The emergence of designed multiple ligands for neurodegenerative disorders.
    Geldenhuys WJ; Youdim MB; Carroll RT; Van der Schyf CJ
    Prog Neurobiol; 2011 Sep; 94(4):347-59. PubMed ID: 21536094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug Development for Neurodegenerative Diseases--a marcus evans conference. Expediting drugs to the market for neurodegenerative disease indications through novel translational efforts, regulatory clarity, and sound trial design. 7-8 April 2009, Boston, MA, USA.
    Morimoto B
    IDrugs; 2009 Jun; 12(6):349-52. PubMed ID: 19517313
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparative analysis of the effects of resveratrol in two apoptotic models: inhibition of complex I and potassium deprivation in cerebellar neurons.
    Alvira D; Yeste-Velasco M; Folch J; Verdaguer E; Canudas AM; Pallàs M; Camins A
    Neuroscience; 2007 Jul; 147(3):746-56. PubMed ID: 17583434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical potential of minocycline for neurodegenerative disorders.
    Blum D; Chtarto A; Tenenbaum L; Brotchi J; Levivier M
    Neurobiol Dis; 2004 Dec; 17(3):359-66. PubMed ID: 15571972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HtrA proteins as targets in therapy of cancer and other diseases.
    Zurawa-Janicka D; Skorko-Glonek J; Lipinska B
    Expert Opin Ther Targets; 2010 Jul; 14(7):665-79. PubMed ID: 20469960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigational melatonin receptor agonists.
    Hardeland R
    Expert Opin Investig Drugs; 2010 Jun; 19(6):747-64. PubMed ID: 20408738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological inhibition of mitochondrial membrane permeabilization for neuroprotection.
    Hisatomi T; Ishibashi T; Miller JW; Kroemer G
    Exp Neurol; 2009 Aug; 218(2):347-52. PubMed ID: 19303007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Melatonin as a structural template in the development of novel drugs for neurodegenerative disorders.
    Korábečný J
    Ceska Slov Farm; 2018; 67(2):51-58. PubMed ID: 30189733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.